Neuraura aims to improve lives by unlocking the field of neuromodulation with next-generation neurosensors. Neuromodulation is a fast-growing area that can treat neurological, psychiatric and sensory conditions, but current challenges include a poor understanding of brain electrophysiology and risks of overstimulation. Neuraura has achieved 100% seizure detection in animal trials with its technology that aims to advance neuromodulation.

1. UNLOCKING
THE BRAIN
May 14th 2019

2. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Disclaimers
GENERAL
The information provided in this presentation pertaining to Neuraura Biotech Inc. (”Neuraura” or the “Company”), its business assets,
strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any
securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities
laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer
to sell such securities.
The Company will only offer securities in those jurisdictions where they may be lawfully offered for sale and the Company’s securities
may be sold only by persons permitted to sell such securities and only to those persons to whom they may be lawfully offered for sale.
No securities commission or similar regulatory authority has passed on the merits of the Company’s securities nor has it reviewed this
presentation and any representation to the contrary is an offence.
While the information in this presentation is believed to be accurate and reliable, Neuraura and its agents, advisors, directors, officers,
employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and
Neuraura expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. Neuraura
reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation
to provide the recipient with access to the amended information or to notify the recipientthereof.
The information contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of
evaluating the Company. The information contained in this presentation supersedes any prior presentation or conversation
concerning the Company. Any information, representations or statements not contained herein shall not be relied upon for any
purpose.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any
person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the
information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or
statements made by, third parties in respect of the matters discussed in this presentation.
CONFIDENTIALITY
This presentation is confidential and is intended, among other things, to present a general outline of the Company. The contents are
not to be reproduced or distributed to the public or press. Each person who has received a copy of this presentation (whether or not
such person purchases any securities) is deemed to have agreed: (i) not to reproduce or distribute this presentation, in whole or in part,
without the prior written consent of the Company, other than to legal, tax, financial and other advisors on a need to know basis; (ii) if
such person has not purchased securities, to return this presentation to the Company upon itsrequest; (iii) without the prior written
consent of the Company, not to disclose any information contained in this presentation except to the extent that such information was
(a) previously known by such person through a source (other than the Company) not bound by any obligation to keep such information
confidential, (b) in the public domain through no fault of such per son, or (c) lawfully obtained at a later date by such person from
sources (other than the Company) not bound by any obligation to keep such information confidential; and (iv) to be responsible for
any disclosure of this presentation, or the information contained herein, by such person or any of its employees, agents or
representatives.
Forward Looking Statements
Certain information in this presentation and oral statements made in any meeting are forward-looking and relate to Neuraura and its
anticipated financial position, business strategy, events and courses of action. Words or phrases such as “anticipate,” “objective,”
“may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is
designed to” orsimilar expressions suggest future outcomes. Forward-looking statements may include, among other things,
statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated
cash needs, our estimates regarding our capital requirements, our need for additional financing; our ability to anticipate the future
needs of our customers; our plans for future products and enhancements of existing products; our future growth strategy and growth
rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Forward looking
statements and financial projections are based on the opinions and estimates of management at the date the statements are made, and
are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements and financial projections.
Although we believe that the expectations reflected in the forward-looking statements and financial projections are reasonable, there
can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance
or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in
the forward-looking statements. By their nature, forward-looking statements and financial projections involve numerous assumptions,
known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the forward-looking
information and financial projections will not occur, which may cause the Company’s actual performance and financial results in future
periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-
looking statements and financial projections. Important factors that could cause actual results to differ materially from expectations
include, but are not limited to: business, economic and capital market conditions; the heavily regulated industry in which the
Company carries on business; current or future laws or regulations and new interpretations of existing laws or regulations; legal and
regulatory requirements; market conditions and the demand and pricing for our products; our relationships with our customers,
developers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our
customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; competition; technology
failures; failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service
disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; our ability to manage risks
inherent in foreign operations; litigation costs and outcomes; our ability to successfully maintain and enforce our intellectual property
rights and defend third party claims of infringement of their intellectual property rights; our ability to manage foreign exchange risk
and working capital; and our ability to manage our growth. Readers are cautioned that this list of factors should not be construed as
exhaustive. The forward-looking statements and any project ions contained in this presentation are expressly qualified by this
cautionary statement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statementsor financial projections, whether as a result of new information, future events or otherwise, after the date on which the
statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on
forward-looking statements or financial projections.
Except where otherwise noted, statements regarding historical fact and statements regarding industry and market trends and
forecastsare based on information obtained from publicly available third party sources of such information. Neuraura has not
undertaken any independent verification of any such third party information.
You should not construe the contents of this presentation as legal, tax, investment or other advice. You should make your own
inquiries and consult your own advisors as to legal, tax, investment, and related matters concerning an investment in the securities of
the Company.

3. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Neuraura will improve the lives of
billions of people by unlocking the
field of neuromodulation with next-
generation neuro sensors

4. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Neuromodulation: Unlocking the Brain
Neuromodulation Opportunity Current Challenges
✓ Fastest growing field in MedTech
✓ Breadth of applications across
neurological, psychiatric and sensory
conditions (e.g Parkinson’s, Epilepsy)
? Poor understanding of the
electrophysiological brain
? Risk of over stimulation resulting in
tissue damage
“…neuromodulation aims to provide direct and long-term solutions
to diseases… [and can] treat some clinical conditions that
medications and surgeries cannot”
Alliance of Advanced Biomedical Engineering (accessed May 2019)

5. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
100% seizure
detection in
animal trials
Secured clinical
and research
collaborations
IP transferred,
4 patents in
process
MRI compatible
for safe imaging
in humans
Neuraura’s Next Generation Neuro Sensors
• 350x smaller
• 20x spatial resolution
• 3x signal resolution
• Record more accurately
• Stimulate more safely
Neuraura
Electrodes
17 µm
Seizure
Legacy Electrodes 6mm

6. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
• Access clinical and scientific
KOLs
• Independently validate
technology
• Realize early unregulated
revenue
• Unique access to brain
insight – “brain atlas”
• FDA Class II 510(k) path
• Significant unmet clinician
and patient needs
• Treat brain disorders
• Breadth of above/below
neck applications
• $9Bn+ market opportunity
and growing
Neuroscience
Research Tools
Epilepsy Surgery
System
Neuraura’s Sensors in
every Brain Implant
Pragmatic and De-risked Commercial Model
2019+
Deep Neuroscience Insight
2020+
Transforming Epilepsy
Treatment
2025+
Standard of Excellence in
Neuromodulation

7. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Neuroscience Research Tools
Problem: Approach:
Poor data quality
Expensive equipment
Sell sensors and hardware to neuroscience researchers
• Execute on research collaborations
• Convert unpaid pilots to paid pilots
• KOLs promote through publications and conferences
• After early traction, sell through channel partners
Existing collaborators:
Neuraura’s Solution: In-Vitro In-Vivo (animal) In-Vivo (human)
3x better signal resolution
Improved repeatability and
efficiency

8. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Epilepsy Surgery System
Problem: Approach:
Poor data quality
Patient in hospital for
weeks
Underserved market
Sell sensors, hardware and software to hospitals
• Conduct small-scale human trials with leading clinicians
• KOLs promote through publications and conferences
• After early traction, sell through channel partners
Neuraura’s Solution:
3x improved data
3D data visualization
Wireless transmission
allows home monitoring
Minimally invasive insertion
Sensors Hardware Software

9. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Neuraura’s Sensors in Every Brain Implant
Problem: Approach:
Legacy sensors risk
brain tissue damage
No granularity for efficient
AI and Machine Learning
Displace legacy sensor technology
• License to established medical device manufacturers
• Co-develop with emerging competitors
• Develop below / above neck devices in-house
Neuraura’s Solution: In-house Applications Co-development Targets Licensing Targets
Precise recording and
stimulation informed by
personalized brain “atlas”
Improved implant longevity

10. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Seeking Investors for $3M+ Seed
2012-17
Initial IP developed & secured
Neuraura incorporated
2018-19 Q2
US$0.5M SAFE and
US$1.4M non-dilutive
Core team hired
Human Prototypes developed
2019 Q3/4
FDA pre-sub meeting
Prepare first human tests
First non-regulated revenue
Raise US$3M+
Cash Flow Forecast (US$M)
(5)
-
5
10
15
20
25
US$M 2018 2019 2020 2021 2022 2023
Revenue - 0.1 1.7 8.1 15.5 22.5
COGS - (0.0) (0.3) (0.9) (1.7) (2.3)
Gross Margin - 0.1 1.4 7.2 13.8 20.3
Indirect Costs (0.1) (1.1) (1.8) (2.0) (2.3) (2.4)
Dep'n and Amort'n (0.0) (0.0) (0.0) (0.1) (0.1) (0.2)
Non-Operating Costs - - - (0.7) - -
Tax 0.0 0.1 0.2 (0.9) (3.1) (4.8)
Net Income (0.1) (0.8) (0.2) 3.6 8.4 12.9
Summary P&L

11. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Strong Multidisciplinary Team
Core Team: Extended Team:
Pierre Wijdenes, PhD
Co-founder and CEO
Human factors and neuro-engineering expert
Business Advisors Scientific & Clinical Advisors
Ray Muzyka
CEO & Founder, ThresholdImpact
Christopher Bissonette
Managing Partner, Pallasite Ventures
Brad Zumwalt
President, Zinc Ventures
Patrick Lor
Managing Partner, Panache Ventures
Robert McKenzie
President, RSM Investments Ltd.
Josh Felker
Founder, BoxOne Ventures
Dr. Walter Hader MD
Head Pediatric Neurosurgery
University of Calgary
Dr. Paolo Federico, MD
Epilepsy Neurologist
University of Calgary
Dr. Cam Teskey, PhD
Director, Neural Plasticity Lab
Hotchkiss Brain Institute
Dr. Naweed Syed, PhD
Scientific Director
Alberta Children’s Hospital
Colin Dalton, PhD
Co-founder and CTO
Microfabrication and tech translation expert
Claire Dixon, MEng MBA
COO
Veteran strategic and operational leader
Bonita Gunning, MSc
Quality Manager
Expert in laboratory-based research Other Key Partners
Kazim Haider
Hardware technician
Intern passionate about neurotech

12. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Why Invest
OPPORTUNITY TIMING FINANCIAL
Platform technology
Multiple paths to revenue
Non-clinical revenue Q3
Epilepsy surgery system
revenue targeted Q4 2020
Seed I closed in Oct 2018
Tripled with non-dilutive
financingFastest growing field in MedTech
Impact humanity
TEAM TECHNOLOGY TRACTION
World class collaborators,
partners and advisors
Multidisciplinary team
Proven in animal trials
Handling tested in cadavers
MRI compatible
4 patents in process
Human-scale prototypes of
sensors, hardware and software
First human tests Q3

13. CONFIDENTIAL & PROPRIETARY | Copyright 2019 Neuraura, all rights reserved
Contact us:
Pierre Wijdenes
Co-Founder, CEO
pierre@neuraura.com
+1.403.830.8112
Claire Dixon
COO
claire@neuraura.com
+1.403.305.0082
Colin Dalton
Co-Founder, CTO
colin@neuraura.com
+1.403.630.9512
With thanks to our community partners
The Community
Opportunity
Fund of Alberta